Chemical Structure (Image 1)
Lapatinib Tablet, Film Coated
Product Images NDC 0480-3237
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lapatinib (NDC 0480-3237). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Image 2)
This text appears to show a chart or table displaying the dosages of Capecitabine and Lapatinib over time in weeks, possibly in relation to progression-free survival. It indicates the dosage values and a time scale up to 100 weeks.*
Figure 2 (Image 3)
This text mentions the cumulative progression-free data for different treatments involving Capecitabine and Lapatinib over time (in weeks). The dosages of Capecitabine and Lapatinib used in the treatments are also provided.*
Figure 3 (Image 4)
This text appears to be a table showing the cumulative progression-free time data for two different treatment regimens involving Letrozole. One regimen involves just Letrozole (2.5 mg), while the other combines Lapatinib (1,500 mg) with Letrozole (2.5 mg). The graph shows time in weeks along the x-axis from 80 to 220 weeks. Unfortunately, no specific data points or results are provided.*
Figure 4 (Image 5)
This text appears to be a schedule or chart showing different combinations of medications administered at various time intervals. It includes Trastuzumab, Lapatinib at different doses, and combination therapies over a period of 45 months.*
Label 250 mg, 150 Tablets (Image 6)
This text provides information about a medication with the NDC code 0480-3237-51. Each tablet contains 398 mg of lapatinib ditosylate, equivalent to 250 g of lapatinib. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C. The medication is manufactured for Teva Pharmaceuticals and comes in a bottle containing 150 tablets. Serialization coding area is also mentioned. It is advised to keep the medication out of reach of children and to use safety closures.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
